Kaygee Investments Pvt. Ltd., an Ipca Labs promoter group entity, has seen a consolidation of shares.

Following the merger of its wholly-owned subsidiaries (Paschim Chemicals & Mexin Medicaments) into itself, KIPL's direct shareholding in Ipca Labs has increased to 6,46,65,448 shares (25.49%). This transaction is an internal restructuring and does not change the overall promoter group stake.